Continuous infusion versus bolus administration of steroids in severe attacks of ulcerative colitis: A randomized, double-blind trial

American Journal of Gastroenterology

Volumn 102, Issue 3, 2007, Pages 601-608

  Bossa, Fabrizio ^a   Fiorella, Serafina ^a   Caruso, Nazario ^a   Accadia, Laura ^a   Napolitano, Grazia ^a   Valvano, Maria Rosa ^a   Andriulli, Angelo ^a   Annese, Vito ^a  

^a CASA SOLLIEVO DELLA SOFFERENZA HOSPITAL   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; CIPROFLOXACIN; CYCLOSPORIN; METHYLPREDNISOLONE; METRONIDAZOLE;

ACNE; ADULT; AGED; ARTICLE; BOLUS INJECTION; CLINICAL TRIAL; CONTINUOUS INFUSION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE DURATION; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FEMALE; HIRSUTISM; HUMAN; INSOMNIA; INTERMETHOD COMPARISON; MAJOR CLINICAL STUDY; MALE; MOON FACE; MUSCLE WEAKNESS; PRIORITY JOURNAL; RANDOMIZATION; RANDOMIZED CONTROLLED TRIAL; REMISSION; SMOKING; STATISTICAL SIGNIFICANCE; STEROID THERAPY; STRIA; TOTAL COLON RESECTION; TREATMENT OUTCOME; ULCERATIVE COLITIS;

ADOLESCENT; ADULT; AGED; COLITIS, ULCERATIVE; COLONOSCOPY; DOUBLE-BLIND METHOD; FEMALE; FOLLOW-UP STUDIES; GLUCOCORTICOIDS; HUMANS; INFUSIONS, INTRAVENOUS; INJECTIONS, INTRAVENOUS; MALE; MIDDLE AGED; RECURRENCE; RETROSPECTIVE STUDIES; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 33847335519     PISSN: 00029270     EISSN: 15720241     Source Type: Journal    
DOI: 10.1111/j.1572-0241.2006.01007.x     Document Type: Article

References (22)

1. Edwards FC, Truelove SC. The course and prognosis of ulcerative colitis. Part 1: Short-term prognosis. Gut 1963;4:300-8.
2. Truelove SC, Lee EG, Willoughby CP, et al. Further experience in the treatment of severe attacks of ulcerative colitis. Lancet 1978;2:1086-8.
3. Campbell S, Travis S, Jewell D. Cyclosporine use in acute ulcerative colitis: A long-term experience. Eur J Gastroenterol Hepatol 2005;17:79-84.
4. Järnerot G, Hertervig E, Friis-Lybi I, et al. Infliximab as rescue therapy in severe to moderately severe ulcerative colitis: A randomized, placebo-controlled study. Gastroenterology 2005;128:1805-11.
5. Rutgeert P, Sandborn WJ, Feagan BG, et al. Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med 2005;353:2462-76.
6. Blomberg B, Järnerot G. Clinical evaluation and management of acute severe colitis. Inflamm Bowel Dis 2000;6:214-27.
7. D'Haens G, Lemmens L, Geboes K, et al. Intravenous cyclosporine versus intravenous corticosteroids as single therapy for severe attacks of ulcerative colitis. Gastroenterology 2001;120:1323-9.
8. Powell-Tuck J, Bown RL, Lennard-Jones JE. A comparison of oral prednisolone given as single or multiple daily doses for active proctocolitis. Scand J Gastroenterol 1978;13:833-7.
9. Lennard-Jones JE, Ritchie JK, Hilder W, et al. Assessment of severity in colitis: A preliminary study. Gut 1975;16:579-84.
10. Schroeder KW, Tremaine WJ, Ilstrup DM. Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis. N Engl J Med 1987;317:1625-9.
11. Järnerot G, Rolny P, Sandberg-Gertzen H. Intensive intravenous treatment of ulcerative colitis. Gastroenterology 1985;89:1005-13.
12. Loftus EV Jr, Alexander GL, Carpenter HA. Cytomegalovirus as an exacerbating factor in ulcerative colitis. J Clin Gastroenterol 1994;19:306-9.
13. Rachima C, Maoz E, Apter S, et al. Cytomegalovirus infection associated with ulcerative colitis in immunocompetent individuals. Postgrad Med 1998;74:486-9.
14. Cottone M, Pietrosi G, Martorana G, et al. Prevalence of cytomegalovirus infection in severe refractory ulcerative and Crohn's colitis. Am J Gastroenterol 2001;96:773-5.
15. Maconi G, Colombo E, Zerbi P, et al. Prevalence, detection rate and outcome of cytomegalovirus infection in ulcerative colitis patients requiring colonic resection. Dig Liver Dis 2005;37:418-23.
16. Solem CA, Loftus EV, Tremaine WJ, et al. Correlation of Creactive protein with clinical, endoscopic, histologic, and radiographic activity in inflammatory bowel disease. Inflamm Bowel Dis 2005;11:707-12.
17. Gabay C, Kushner I. Acute-phase proteins and other systemic responses to inflammation. N Engl J Med 1999;340:448-54.
18. Lindgren SC, Flood LM, Kilander AF, et al. Early predictors of glucocorticosteroid treatment failure in severe and moderately severe attacks of ulcerative colitis. Eur J Gastroenterol Hepatol 1998;10:831-5.
19. Travis SPL, Farrant JM, Nolan DJ, et al. Predicting outcome in severe ulcerative colitis. Gut 1996;38:905-10.
20. Chakavarty BJ. Predictors of the rate of medical treatment failure in ulcerative colitis. Am J Gastroenterol 1999;88:852-5.
21. Benazzato L, D'Incà R, Grigoletto F, et al. Prognosis of severe attacks in ulcerative colitis: Effect of intensive medical treatment. Dig Liver Dis 2004;36:461-6.
22. Birrenbach T, Böcker U. Inflammatory bowel disease and smoking. A review of epidemiology, pathophysiology, and therapeutic implication. Inflamm Bowel Dis 2004;10:848-59.